Abstract
Objective:
The feasibility of a definitive trial was tested to evaluate individualized homeopathic medicines (IHMs) for the treatment of vitiligo.
Design:
This was a double-blind randomized (1:1) placebo-controlled pilot trial conducted at the National Institute Homeopathy, India. Sixty patients with vitiligo were included in the study.
Interventions:
IHMs and identical-looking placebos at 50-millesimal (LM) potencies.
Outcome measures:
Feasibility issues and scores from the Vitiligo Area Scoring Index (VASI), Vitiligo-specific Quality-of-life instrument (VitiQoL), and Dermatology Life Quality Index (DLQI) were measured at baseline and after 3 and 6 months.
Results:
The recruitment and retention rates were satisfactory. Mean reductions in the outcome measures were higher in the IHM group than placebo.
Conclusions:
Definitive efficacy trials are warranted.
Clinical Trials Registry—India: CTRI/2018/10/016160; secondary identifier UTN: U1111-1221-7704.
Get full access to this article
View all access options for this article.
References
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
